

IMMUCELL CORP /DE/  
Form 8-K  
February 01, 2018

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report: January 30, 2018**

(Date of earliest event reported)

**ImmuCell Corporation**

(Exact name of registrant as specified in its charter)

**DE**

(State or other jurisdiction  
of incorporation)

**001-12934**

(Commission File Number)

**01-0382980**

(IRS Employer  
Identification Number)

**56 Evergreen Drive**

**Portland, Maine**

(Address of principal executive offices)

**04103**

(Zip Code)

**207-878-2770**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: IMMUCCELL CORP /DE/ - Form 8-K

- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 –Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; and Compensatory Arrangements of Certain Officers**

On January 30, 2018, Mr. Steven T. Rosgen and Ms. Bobbi Jo Brockmann were appointed to serve as members of the Company’s Board of Directors, effective January 30, 2018. These recommendations were made by the Nominating Committee of the Board and approved by the Board of Directors.

**Item 9.01 –Financial Statements and Exhibits**

(d) Exhibits

**Exhibit No. Description**

EX-99.1 Press Release of ImmuCell Corporation dated January 30, 2018.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 1, 2018 **IMMUCELL  
CORPORATION**

By: */s/ Michael F. Brigham*  
Michael F. Brigham  
President and CEO

**Exhibit Index**

**Exhibit No. Description**

EX-99.1 Press Release of ImmuCell Corporation dated January 30, 2018.